 Sequential administration recombinant human dacarbazine metastatic melanoma multicenter phase II study Twenty-five assessable patients metastatic melanoma multicenter phase II study induction cycles human recombinant continuous intravenous IV infusion days days Dacarbazine DTIC IV bolus day cycle weeks Maintenance therapy weeks completion induction treatment days DTIC IV weeks total weeks patients complete partial Stable disease patients None patients sites metastases Maximum response first months treatment Progression-free periods months complete responders months partial responders months patients stable disease months Toxicity fever skin rash fatigue anorexia diarrhea patients patients weight gain patients intensive care observation treatment myocardial injury patient ventricular tachycardia hypotension oliguria sepsis Sequential treatment DTIC effective